|
Published by: Global Markets Direct
Published: Jan. 23, 2012 - 162 Pages
Table of Contents- Introduction
- Global Markets Direct Report Coverage
- Arthritis Overview
- Therapeutics Development
- An Overview of Pipeline Products for Arthritis
- Arthritis Therapeutics under Development by Companies
- Arthritis Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Arthritis Therapeutics - Products under Development by Companies
- Arthritis Therapeutics - Products under Investigation by Universities/Institutes
- Companies Involved in Arthritis Therapeutics Development
- Baxter International Inc.
- Johnson & Johnson
- Abbott Laboratories
- Seikagaku Corporation
- Celltrion, Inc.
- Sylentis
- Novartis AG
- Savient Pharmaceuticals, Inc.
- Bone Medical Limited
- 3SBio Inc.
- Ardea Biosciences, Inc.
- BioCryst Pharmaceuticals, Inc.
- CSL Limited
- Regeneron Pharmaceuticals, Inc.
- LG Life Sciences, Ltd
- Galapagos NV
- Oscotec Inc.
- AnaMar Medical AB
- Metabolex, Inc
- Wellstat Therapeutics Corporation
- CREABILIS Therapeutics S.r.l.
- Opsona Therapeutics Ltd.
- PLx Pharma Inc.
- TissueGene, Inc.
- Endocyte, Inc.
- Cornerstone Therapeutics Inc.
- Nuon Therapeutics, Inc.
- NasVax Ltd.
- Ferring Pharmaceuticals, Inc.
- Kemin Industries, Inc.
- Amplimmune, Inc.
- RNL BIO Co., Ltd.
- Arthritis - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- CSL324 - Drug Profile
- RDEA594 - Drug Profile
- RDEA684 - Drug Profile
- Ilaris - Drug Profile
- MBX-102 - Drug Profile
- AMP-110 - Drug Profile
- Stelara - Drug Profile
- PNXXXX - Drug Profile
- BCX4208 - Drug Profile
- GLPG0555 - Drug Profile
- Arcalyst - Drug Profile
- TissueGene-C - Drug Profile
- Krystexxa - Drug Profile
- HMGB1 Program - Drug Profile
- Piroxicam - Drug Profile
- Meloxicam - Drug Profile
- PL 5100 Diclofenac - Drug Profile
- PL 4100 Indomethacin - Drug Profile
- KPE06001 - Drug Profile
- NU1618 - Drug Profile
- Pegsitacase - Drug Profile
- EC0746 - Drug Profile
- RDEA594 + Allopurinol - Drug Profile
- RDEA594 + Febuxostat - Drug Profile
- Orfadin - Drug Profile
- BCX4208 + Allopurinol - Drug Profile
- CT340 - Drug Profile
- Adalimumab - Drug Profile
- Zoledronate - Drug Profile
- Drug For Arthritis - Drug Profile
- MIF Inhibitors - Drug Profile
- CT-P17 - Drug Profile
- DIS-BIO-OA01 - Drug Profile
- Focetria - Drug Profile
- Core Targeted Therapy - Drug Profile
- Humanized antibody conjugate - Drug Profile
- Anti-aCD3 Mab - Drug Profile
- BN005 - Drug Profile
- BN008 - Drug Profile
- NanoActive Indomethacin - Drug Profile
- GLPG0778 - Drug Profile
- LC350189 - Drug Profile
- Inflammasome Modulator Program - Drug Profile
- HZN-602 - Drug Profile
- 5-HT2 Receptor Antagonist - Drug Profile
- XO Inhibitor - Drug Profile
- Next Generation URAT1 Inhibitor - Drug Profile
- Anti-MIF Antibody - Drug Profile
- Jointstem - Drug Profile
- OCT-SG815 - Drug Profile
- IL-23 Receptor Antagonists - Drug Profile
- SYK Inhibitors - Drug Profile
- ADAMTS-5 Inhibitors - Drug Profile
- Selected Activated T Cell Death Inducers - Drug Profile
- RDEA3170 - Drug Profile
- Arthritis Therapeutics - Drug Profile Updates
- Arthritis Therapeutics - Discontinued Products
- Arthritis Therapeutics - Dormant Products
- Arthritis - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Arthritis, H1 2012
- Products under Development for Arthritis - Comparative Analysis, H1 2012
- Number of Products under Development by Companies, H1 2012
- Number of Products under Development by Companies, H1 2012 (Contd..1)
- Number of Products under Development by Companies, H1 2012 (Contd..2)
- Number of Products under Investigation by Universities/Institutes, H1 2012
- Comparative Analysis by Late Stage Development, H1 2012
- Comparative Analysis by Mid Clinical Stage Development, H1 2012
- Comparative Analysis by Early Clinical Stage Development, H1 2012
- Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
- Products under Development by Companies, H1 2012
- Products under Development by Companies, H1 2012 (Contd..1)
- Products under Development by Companies, H1 2012 (Contd..2)
- Products under Development by Companies, H1 2012 (Contd..3)
- Products under Investigation by Universities/Institutes, H1 2012
- Baxter International Inc., H1 2012
- Johnson & Johnson, H1 2012
- Abbott Laboratories, H1 2012
- Seikagaku Corporation, H1 2012
- Celltrion, Inc., H1 2012
- Sylentis, H1 2012
- Novartis AG, H1 2012
- Savient Pharmaceuticals, Inc., H1 2012
- Bone Medical Limited, H1 2012
- 3SBio Inc., H1 2012
- Ardea Biosciences, Inc., H1 2012
- BioCryst Pharmaceuticals, Inc., H1 2012
- CSL Limited, H1 2012
- Regeneron Pharmaceuticals, Inc., H1 2012
- LG Life Sciences, Ltd, H1 2012
- Galapagos NV, H1 2012
- Oscotec Inc., H1 2012
- AnaMar Medical AB, H1 2012
- Metabolex, Inc, H1 2012
- Wellstat Therapeutics Corporation, H1 2012
- CREABILIS Therapeutics S.r.l., H1 2012
- Opsona Therapeutics Ltd., H1 2012
- PLx Pharma Inc., H1 2012
- TissueGene, Inc., H1 2012
- Endocyte, Inc., H1 2012
- Cornerstone Therapeutics Inc., H1 2012
- Nuon Therapeutics, Inc., H1 2012
- NasVax Ltd., H1 2012
- Ferring Pharmaceuticals, Inc., H1 2012
- Kemin Industries, Inc., H1 2012
- Amplimmune, Inc., H1 2012
- RNL BIO Co., Ltd., H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Combination Products, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- Arthritis Therapeutics - Drug Profile Updates
- Arthritis Therapeutics - Discontinued Products
- Arthritis Therapeutics - Dormant Products
- List of Figures
- Number of Products under Development for Arthritis, H1 2012
- Products under Development for Arthritis - Comparative Analysis, H1 2012
- Products under Development by Companies, H1 2012
- Products under Investigation by Universities/Institutes, H1 2012
- Late Stage Products, H1 2012
- Mid Clinical Stage Products, H1 2012
- Early Clinical Stage Products, H1 2012
- Discovery and Pre-Clinical Stage Products, H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Combination Products, H1 2012
- Assessment by Route of Administration, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- Assessment by Stage and Molecule Type, H1 2012
AbstractArthritis - Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'Arthritis - Pipeline Review, H1 2012', provides an overview of the Arthritis therapeutic pipeline. This report provides information on the therapeutic development for Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Arthritis. 'Arthritis - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Arthritis.
- A review of the Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Arthritis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Arthritis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Arthritis pipeline depth and focus of Arthritis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
